{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T03:14:04Z","timestamp":1772248444367,"version":"3.50.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T00:00:00Z","timestamp":1599868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004087","name":"Restless Legs Syndrome Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004087","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Study Objectives<\/jats:title>\n                  <jats:p>Restless legs syndrome (RLS) is a sensory-motor neurological disorder. Low dose opioid medications are prescribed for treatment-refractory RLS. We describe baseline and 1-year longitudinal dosing and symptom outcomes for the National RLS Opioid Registry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Individuals currently taking a prescribed opioid for diagnosed RLS are included in the registry. Information on initial and current opioid dosages, side effects, past and current concomitant RLS treatments, RLS severity, psychiatric history, and opioid abuse risk factors were collected at baseline. Follow-up online surveys were performed at 6 months and 1-year.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Participants (n = 500) are primarily white, elderly, educated, and retired. Half of all subjects are on opioid monotherapy. Nearly 50% of all subjects are taking methadone, and one-quarter are taking oxycodone formulations. The median total daily opioid dose is 30.0 morphine milligram equivalents (MME). At baseline, three-quarters of registry participants had been taking a prescribed opioid for RLS for more than 1 year and one-third for more than 5 years, and had mild-moderate RLS symptoms. At 1-year follow-up, 31.2% increased dose (median = 10 MME) and 16.0% decreased dose of their opioid. An MME increase \u226525 was associated with: opioid use for non-RLS pain, &amp;lt;1 year of opioid use, opioid switch to methadone, and discontinuation of non-opioid RLS medications which, combined, accounted for 91.7% of those with 1-year follow-up increases \u226525 MME.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In refractory RLS, prescribed opioids are generally used at low doses with good efficacy. Longitudinally over 1 year, roughly one-third of participants increased their prescribed opioid dose, though generally by small amounts, with larger dose increases accounted for by predictable features.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/sleep\/zsaa183","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T09:54:09Z","timestamp":1599904449000},"source":"Crossref","is-referenced-by-count":15,"title":["Baseline and 1-year longitudinal data from the National Restless Legs Syndrome Opioid Registry"],"prefix":"10.1093","volume":"44","author":[{"given":"John W","family":"Winkelman","sequence":"first","affiliation":[{"name":"Sleep Disorders Clinical Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA"},{"name":"Department of Psychiatry and Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Purks","sequence":"additional","affiliation":[{"name":"Larner College of Medicine at the University of Vermont, Burlington, VT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Wipper","sequence":"additional","affiliation":[{"name":"Sleep Disorders Clinical Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,9,12]]},"reference":[{"issue":"8","key":"2021021210384485400_CIT0001","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.sleep.2014.03.025","article-title":"Restless legs syndrome\/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria\u2013history, rationale, description, and significance","volume":"15","author":"Allen","year":"2014","journal-title":"Sleep Med."},{"issue":"11","key":"2021021210384485400_CIT0002","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/archinte.165.11.1286","article-title":"Restless legs syndrome prevalence and impact: REST general population study","volume":"165","author":"Allen","year":"2005","journal-title":"Arch Intern Med."},{"key":"2021021210384485400_CIT0003","first-page":"CD006009","article-title":"Dopamine agonists for restless legs syndrome","volume":"3","author":"Scholz","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"2021021210384485400_CIT0004","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.sleep.2010.11.002","article-title":"A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome","volume":"12","author":"Silver","year":"2011","journal-title":"Sleep Med."},{"issue":"5","key":"2021021210384485400_CIT0005","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.sleep.2011.03.003","article-title":"Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample","volume":"12","author":"Allen","year":"2011","journal-title":"Sleep Med."},{"issue":"5","key":"2021021210384485400_CIT0006","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40263-015-0250-2","article-title":"Long-term treatment of restless legs syndrome (RLS): an approach to management of worsening symptoms, loss of efficacy, and augmentation","volume":"29","author":"Mackie","year":"2015","journal-title":"CNS Drugs."},{"issue":"12","key":"2021021210384485400_CIT0007","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S1474-4422(13)70239-4","article-title":"Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension","volume":"12","author":"Trenkwalder","year":"2013","journal-title":"Lancet Neurol."},{"issue":"3","key":"2021021210384485400_CIT0008","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/mds.20359","article-title":"Methadone for refractory restless legs syndrome","volume":"20","author":"Ondo","year":"2005","journal-title":"Mov Disord."},{"issue":"6","key":"2021021210384485400_CIT0009","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/mds.1214","article-title":"Long-term follow-up on restless legs syndrome patients treated with opioids","volume":"16","author":"Walters","year":"2001","journal-title":"Mov Disord."},{"issue":"3","key":"2021021210384485400_CIT0010","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.sleep.2007.04.021","article-title":"Validation of the Hopkins telephone diagnostic interview for restless legs syndrome","volume":"9","author":"Hening","year":"2008","journal-title":"Sleep Med."},{"issue":"5","key":"2021021210384485400_CIT0011","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.sleep.2007.03.022","article-title":"Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute","volume":"8","author":"Garc\u00eda-Borreguero","year":"2007","journal-title":"Sleep Med."},{"issue":"2","key":"2021021210384485400_CIT0012","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1389-9457(02)00258-7","article-title":"Validation of the international restless legs syndrome study group rating scale for restless legs syndrome","volume":"4","author":"Walters","year":"2003","journal-title":"Sleep Med."},{"issue":"12","key":"2021021210384485400_CIT0013","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry."},{"issue":"6","key":"2021021210384485400_CIT0014","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1526-4637.2005.00072.x","article-title":"Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool","volume":"6","author":"Webster","year":"2005","journal-title":"Pain Med."},{"key":"2021021210384485400_CIT0015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-3-79","article-title":"The reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a trial population","volume":"3","author":"Abetz","year":"2005","journal-title":"Health Qual Life Outcomes."},{"issue":"3","key":"2021021210384485400_CIT0016","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0304-3959(75)90044-5","article-title":"The McGill Pain Questionnaire: major properties and scoring methods","volume":"1","author":"Melzack","year":"1975","journal-title":"Pain"},{"issue":"4","key":"2021021210384485400_CIT0017","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1389-9457(00)00065-4","article-title":"Validation of the Insomnia Severity Index as an outcome measure for insomnia research","volume":"2","author":"Bastien","year":"2001","journal-title":"Sleep Med."},{"issue":"6","key":"2021021210384485400_CIT0018","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the Epworth sleepiness scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep"},{"issue":"6","key":"2021021210384485400_CIT0019","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/PSY.0000000000000322","article-title":"Patient health questionnaire anxiety and depression scale: initial validation in three clinical trials","volume":"78","author":"Kroenke","year":"2016","journal-title":"Psychosom Med."},{"issue":"10","key":"2021021210384485400_CIT0020","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med."},{"issue":"9","key":"2021021210384485400_CIT0021","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med."},{"key":"2021021210384485400_CIT0022","author":"Centers for Medicare and Medicaid Services."},{"issue":"4","key":"2021021210384485400_CIT0023","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/sleep\/16.4.327","article-title":"Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo","volume":"16","author":"Walters","year":"1993","journal-title":"Sleep."},{"issue":"15","key":"2021021210384485400_CIT0024","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC guideline for prescribing opioids for chronic pain\u2014United States, 2016","volume":"315","author":"Dowell","year":"2016","journal-title":"JAMA."},{"issue":"5","key":"2021021210384485400_CIT0025","first-page":"892","article-title":"Variability in opioid equivalence calculations","volume":"17","author":"Rennick","year":"2016","journal-title":"Pain Med."},{"issue":"1","key":"2021021210384485400_CIT0026","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1389-9457(99)00012-X","article-title":"Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset","volume":"1","author":"Allen","year":"2000","journal-title":"Sleep Med."},{"issue":"11","key":"2021021210384485400_CIT0027","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1007\/s00415-004-0552-7","article-title":"Analysis of familial and sporadic restless legs syndrome in age of onset, gender, and severity features","volume":"251","author":"Hanson","year":"2004","journal-title":"J Neurol."},{"issue":"7","key":"2021021210384485400_CIT0028","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.sleep.2013.05.016","article-title":"The long-term treatment of restless legs syndrome\/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group","volume":"14","author":"Garcia-Borreguero","year":"2013","journal-title":"Sleep Med."},{"issue":"5","key":"2021021210384485400_CIT0029","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/AJP.0000000000000133","article-title":"Painful restless legs syndrome: a severe, burning form of the disease","volume":"31","author":"Karroum","year":"2015","journal-title":"Clin J Pain."},{"issue":"1","key":"2021021210384485400_CIT0030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00415-005-0604-7","article-title":"\u201cAnxietas tibiarum\u201d. Depression and anxiety disorders in patients with restless legs syndrome","volume":"252","author":"Winkelmann","year":"2005","journal-title":"J Neurol."},{"key":"2021021210384485400_CIT0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.sleep.2018.09.019","article-title":"Suicidal thought and behavior in individuals with restless legs syndrome","volume":"54","author":"Para","year":"2019","journal-title":"Sleep Med."},{"issue":"8","key":"2021021210384485400_CIT0032","doi-asserted-by":"crossref","first-page":"e199966","DOI":"10.1001\/jamanetworkopen.2019.9966","article-title":"Association of restless legs syndrome with risk of suicide and self-harm","volume":"2","author":"Zhuang","year":"2019","journal-title":"JAMA Netw Open."},{"issue":"12","key":"2021021210384485400_CIT0033","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1176\/appi.ajp.2016.15091179","article-title":"Pain as a predictor of opioid use disorder in a nationally representative sample","volume":"173","author":"Blanco","year":"2016","journal-title":"Am J Psychiatry."},{"issue":"1","key":"2021021210384485400_CIT0034","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.mayocp.2017.11.007","article-title":"The appropriate use of opioids in the treatment of refractory restless legs syndrome","volume":"93","author":"Silber","year":"2018","journal-title":"Mayo Clin Proc."}],"container-title":["Sleep"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/sleep\/advance-article-pdf\/doi\/10.1093\/sleep\/zsaa183\/33863711\/zsaa183.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/sleep\/article-pdf\/44\/2\/zsaa183\/36245278\/zsaa183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/sleep\/article-pdf\/44\/2\/zsaa183\/36245278\/zsaa183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T00:51:23Z","timestamp":1613177483000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/sleep\/article\/doi\/10.1093\/sleep\/zsaa183\/5904763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,12]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,9,12]]},"published-print":{"date-parts":[[2021,2,12]]}},"URL":"https:\/\/doi.org\/10.1093\/sleep\/zsaa183","relation":{},"ISSN":["0161-8105","1550-9109"],"issn-type":[{"value":"0161-8105","type":"print"},{"value":"1550-9109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2,1]]},"published":{"date-parts":[[2020,9,12]]},"article-number":"zsaa183"}}